Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label ExtensionOriginal Article Published on 2024-02-282024-09-04 Journal: Journal of Crohn's and Colitis [Category] 대상포진, [키워드] Ozanimod S1P receptor modulator ulcerative colitis [DOI] 10.1093/ecco-jcc/jjad146 PMC 바로가기 [Article Type] Original Article
Clinician’s Guide to Using Ozanimod for the Treatment of Ulcerative ColitisReview Article Published on 2023-12-122024-09-04 Journal: Journal of Crohn's and Colitis [Category] 대상포진, [키워드] Ozanimod S1P receptor modulator ulcerative colitis [DOI] 10.1093/ecco-jcc/jjad112 PMC 바로가기 [Article Type] Review Article
Oral small molecule agents in management of ulcerative colitis: fact or fancy?Review Article Published on 2023-08-112024-09-04 Journal: Turkish Journal of Medical Sciences [Category] 대상포진, [키워드] Ozanimod sphingosine-1-phosphate receptor modulators Tofacitinib ulcerative colitis Upadacitinib [DOI] 10.55730/1300-0144.5722 PMC 바로가기 [Article Type] Review Article
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trialClinical Trials and Therapeutics Published on 2022-06-282024-09-04 Journal: Multiple Sclerosis Journal [Category] 대상포진, [키워드] adverse events Clinical efficacy extension study multiple sclerosis Ozanimod sphingosine 1-phosphate receptor modulators [DOI] 10.1177/13524585221102584 PMC 바로가기 [Article Type] Clinical Trials and Therapeutics
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE StudyOriginal Article Published on 2021-07-132024-09-04 Journal: Journal of Crohn's and Colitis [Category] 대상포진, [키워드] clinical trial Ozanimod ulcerative colitis [DOI] 10.1093/ecco-jcc/jjab012 PMC 바로가기 [Article Type] Original Article
The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial입원한 COVID-19 환자의 결과 개선에 대한 파모티딘의 효능: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2020-10-132022-08-13 Journal: Trials [Category] MERS, SARS, 임상, [키워드] Alanine Alanine transaminase alcoholism All participant All participants allergies allergy allocation approved ARMS aspartate Aspartate transaminase assigned assumption Bandar Abba Bandar Abbas baseline Blinding block randomization blood count Care Chronic kidney disease clearance clinical clinical trial clinical trials code Committee company comparator Comparator group complete blood count concealed control group control groups COVID-19 COVID-19 patient COVID-19 patients creatinine creatinine clearance criteria Dasatinib dialysis discharge dissemination dosage drug therapy electrocardiogram element eligibility criteria End-stage renal disease ethics committee Evidence evidence of excluded expected Famotidine G6PD Glucose Glucose 6 phosphate grouping groups Hepatitis hepatitis C Hospitalized Immunocompromised Immunocompromised patients Infection Intervention Kidney disease Lactate lactate dehydrogenase lead limit Liver disease Local lung infiltration maximum Medical Science Medical Sciences moderate need for dialysis Neratinib normal limit number objective online tool oral contraceptives outcome outcome assessor outcome assessors oxygen oxygen saturation Ozanimod participant Patient patients patients with COVID-19 Pazopanib PCR test pharmaceutical Pharmaceutical Company phosphate Placebo placebo-controlled porphyria positive Pregnancy protocol psoriasis random randomisation randomised randomised controlled trial randomized clinical trial Randomly randomly divided receive recruitment Registered registry renal renal disease renal failure reported Research question researcher respiration rate responsible Rilpivirine Sample size sample size calculation sequence sequence information single-blind Siponimod Standard study drug Study protocol subject submitted technology temperature the ethics committee therapy title Tizanidine transaminase Treatment treatment group Treatment protocol treatment protocols Trial registration two group two groups university Version website were measured written consent [DOI] 10.1186/s13063-020-04773-6 PMC 바로가기 [Article Type] Letter
Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challengesReviews Published on 2017-09-052024-09-04 Journal: Therapeutic Advances in Gastroenterology [Category] 대상포진, [키워드] AJM300 filgotinib fingolimod inflammatory bowel diseases mongersen oral therapy Ozanimod Phosphatidylcholine Tofacitinib [DOI] 10.1177/1756283X17727388 PMC 바로가기 [Article Type] Reviews
Janus kinase antagonists and other novel small molecules for the treatment of Crohn’s diseaseArticle Published on 2017-05-182024-09-04 Journal: Gastroenterol Clin North Am : book_id PMC인데 pubmed로 기재 [Category] 대상포진, [키워드] Crohn’s disease filgotinib JAK inhibitor mongersen Ozanimod SMAD7 small molecule sphingosine-1-phosphate receptor TGF-β [DOI] 10.1016/j.gtc.2017.05.015 PMC 바로가기 [Article Type] Article